NGM Phase IIb NASH Failure Could Darken Competitors’ Prospects

 
• By Joseph Haas

NGM will not proceed with a Phase III study in F2/F3 NASH following failure to show fibrosis benefit in Phase IIb. Analysts say this setback could portend disappointing readouts for other NASH players.

Business strategy failure as a despair metaphor or financial market drop and psychological burnout symbol in a 3D illustration style.
NGM hopes investors will be enthused about its pipeline as it moves away from NASH

More from Clinical Trials

More from R&D